PABLO
GUISADO VASCO
PROFESOR
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (8)
2021
-
SARS-CoV-2 infection in patients with primary Sjögren syndrome: Characterization and outcomes of 51 patients
Rheumatology (United Kingdom), Vol. 60, Núm. 6, pp. 2946-2957
2019
-
Safety and efficacy of prolonged use of dalbavancin in bone and joint infections
Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 5
-
Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients
Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106
-
The Big Data Sjögren consortium: A project for a new data science era
Clinical and Experimental Rheumatology, Vol. 37, pp. S19-S23
2018
-
Dalbavancin in the treatment of different gram-positive infections: a real-life experience
International Journal of Antimicrobial Agents, Vol. 51, Núm. 4, pp. 571-577
-
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)
Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111
-
Severe, life-threatening phenotype of primary Sjögren's syndrome: Clinical characterisation and outcomes in 1580 patients (the GEAS-SS Registry)
Clinical and Experimental Rheumatology, Vol. 36, pp. S121-S129
2012
-
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series
Leukemia and Lymphoma, Vol. 53, Núm. 5, pp. 812-819